☆ 4.4 Article

A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement

PEDIATRIC BLOOD & CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements

Alexander Popov et al.

Summary: This study evaluated the concordance between minimal residual disease (MRD) results obtained by multicolour flow cytometry (MFC) and polymerase chain reaction for fusion gene transcripts (FGTs) in infants with acute lymphoblastic leukaemia (ALL) associated with rearrangement of the KMT2A gene (KMT2A-r). The study found a concordance rate of 87.4% between the two methods and concluded that combining them can provide a more accurate risk assessment.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Letter Oncology

Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008

Alexander Popov et al.

LEUKEMIA RESEARCH (2023)

添加到收藏夹

Editorial Material Oncology

A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008

Alexander Popov et al.

LEUKEMIA RESEARCH (2022)

添加到收藏夹

Article Hematology

Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction

Iman Sidhom et al.

Summary: Improved outcomes in children with very-low-risk (VLR) ALL can be achieved with low-intensity therapy based on presenting features and minimal residual disease (MRD) levels. However, patients with MRD levels between 0.001% and <0.01% during early remission induction may have a higher risk of relapse compared to those with undetectable residual leukemia.

BLOOD (2021)

添加到收藏夹

Article Oncology

Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group

Rachel E. Rau et al.

Summary: For NCI standard-risk B-ALL patients with MRD >= 0.01% at both end of induction and end of consolidation, routine use of HSCT may not be necessary as they have higher survival rates compared to those with lower MRD levels.

PEDIATRIC BLOOD & CANCER (2021)

添加到收藏夹

Article Oncology

An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report

Margarita Maurer-Granofszky et al.

Summary: Standardization of flow cytometric assessment of minimal residual disease in acute lymphoid leukemia is essential for international collaborative trials. A comprehensive training and quality control program is needed to achieve concordant results across multiple laboratories. Continuous education and quality control measures significantly improve inter-laboratory concordance rates and risk estimates in independent patient cohorts.

CANCERS (2021)

添加到收藏夹

Article Hematology

Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa et al.

BLOOD (2020)

添加到收藏夹

Article Oncology

Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children?s Oncology Group Trial AALL0331

Kelly W. Maloney et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Letter Oncology

Prognostic significance of flow cytometry MRD log reduction during induction treatment of childhood ALL

Maria Ampatzidou et al.

LEUKEMIA & LYMPHOMA (2019)

添加到收藏夹

Article Oncology

Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia

N. Toft et al.

LEUKEMIA (2018)

添加到收藏夹

Article Oncology

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)

Martin Schrappe et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

Rob Pieters et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Review Medical Laboratory Technology

Detection of Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia

Giuseppe Gaipa et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)

添加到收藏夹

Article Hematology

Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia

Giuseppe Gaipa et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

添加到收藏夹

Article Oncology

Minimal Residual Disease-Guided Treatment Deintensification for Children With Acute Lymphoblastic Leukemia: Results From the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study

Allen Eng Juh Yeoh et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Review Oncology

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

M. Brueggemann et al.

LEUKEMIA (2010)

添加到收藏夹

Article Oncology

Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

Giuseppe Basso et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Medical Laboratory Technology

Standardization of Flow Cytometric Minimal Residual Disease Evaluation in Acute Lymphoblastic Leukemia: Multicentric Assessment Is Feasible

Michael Norbert Dworzak et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2008)

添加到收藏夹

Article Oncology

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia

T. Flohr et al.

LEUKEMIA (2008)

添加到收藏夹

Article Oncology

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data

V. H. J. van der Velden et al.

LEUKEMIA (2007)

添加到收藏夹

Article Hematology

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

E Coustan-Smith et al.

BLOOD (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.